Century Therapeutics, Inc.
NASDAQ:IPSCBiotechnology
Healthcare
$1.32 +0.48%
+$0.01 today
- Market cap
- $239.71M
- Beta
- 1.57
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.25
52W Low $0.44High $3.04
Volume 0.82M
Average 1.12M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$103.88M
FY 2025 · Annual
Investing Cash Flow
$107.50M
FY 2025 · Annual
+126.4% YoYFinancing Cash Flow
$173,000.00
FY 2025 · Annual
-99.8% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (95.82M) | (130.93M) | (136.67M) | (126.57M) | (9.58M) |
| Depreciation & Amortization | 3.75M | 8.44M | 13.04M | 13.3M | 13.1M |
| Deferred Income Tax | 0 | 0 | 0 | 870K | (73K) |
| Stock-Based Compensation | 4.66M | 10.67M | 14.62M | 12.69M | 6.84M |
| Change in Working Capital | (2.8M) | 123.95M | 9.38M | (9.28M) | (114.55M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.85M) | (4.79M) | (2.36M) | (1.47M) | 1.56M |
| Other Working Capital | (949K) | 128.73M | 11.74M | (7.81M) | (116.12M) |
| Other Non-Cash Items | 1.21M | 1.93M | 11.28M | (1.15M) | 389K |
| Operating Cash Flow | (89M) | 14.05M | (88.35M) | (110.14M) | (103.88M) |
| Capital Expenditures | (44.97M) | (30.6M) | (13.74M) | (154K) | (848K) |
| Acquisitions (Net) | 0 | (238.22M) | 0 | (9.61M) | 0 |
| Purchases of Investments | (330.03M) | (254M) | (209.03M) | (119.55M) | (51.17M) |
| Sales of Investments | 76.67M | 271.48M | 283.9M | 176.79M | (51.17M) |
| Other Investing Activities | 0 | 238.22M | 0 | 0 | 210.7M |
| Investing Cash Flow | (298.34M) | (13.13M) | 61.13M | 47.48M | 107.5M |
| Debt Repayment | 0 | 0 | (10.24M) | 0 | 0 |
| Common Stock Issued | 221.62M | 27.16M | 516K | 74.56M | 173K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 36.53M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 417.77M | 27.16M | (9.73M) | 74.56M | 173K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 30.43M | 28.08M | (36.94M) | 11.91M | 3.8M |
| Free Cash Flow | (133.97M) | (16.55M) | (102.08M) | (110.29M) | (104.72M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$9.6M
+ D&A$13.1M
+ Stock-Based Comp$6.8M
- Deferred Tax-$73.0K
- Working Capital-$114.6M
+ Other Non-Cash$389.0K
= Operating Cash Flow-$103.9M
- Capex-$848.0K
= Free Cash Flow-$104.7M
Analysis
FY2025 free cash flow is -$104.7M. FCF conversion is 1093.2% of net income. Operating cash flow was -$103.9M, with capex of -$848.0K. The largest bridge item is Working Capital at -$114.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 | |
| 8-K | Current report | Oct 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 15, 2026 |
Does IPSC generate free cash flow?
Century Therapeutics, Inc. (IPSC) generated -$104.72M of free cash flow in fiscal 2025.
How much operating cash flow does IPSC produce?
Operating cash flow was -$103.88M, before capital expenditures of $848,000.00.
Continue the stock analysis
Jump to another research area for this company.